Artal Group’s Pliant Therapeutics PLRX Stock Holding History

Artal Group’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,490	Closed	-$26K	–	109
2023 Q3	$26K	Hold	1,490	–	–	﹤0.01%	101
2023 Q2	$27K	Sell	1,490 -253,595	-99%	-$6M	﹤0.01%	117
2023 Q1	$6.79M	Buy	+255,085	New	+$7.26M	0.4%	54

Other funds holding PLRX

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Artal Group's PLRX Position: Q4 2023 in Review

Artal Group sold out of Pliant Therapeutics (PLRX) in Q4 2023, closing a stake of 1,490 shares — an estimated $26K sold.

Artal Group first reported a position in PLRX in Q1 2023 and held it in 3 quarters. The position peaked at $6.79M in Q1 2023. 134 funds tracked by Wall St. Rank hold PLRX as of Q4 2023.

Artal Group reported no remaining Pliant Therapeutics position as of Q4 2023 after selling out during the quarter.
Artal Group sold 1,490 Pliant Therapeutics shares in Q4 2023, an estimated $26K.
Artal Group first reported a position in Pliant Therapeutics in Q1 2023 and held it in 3 quarters.
Artal Group's Pliant Therapeutics position peaked at $6.79M in Q1 2023.
134 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q4 2023.

Based on Artal Group's 13F filing for Q4 2023, filed 9 Feb 2024.